

Teva improves the lives of patients around the world every day with our quality medicines, and we want to continue to do so for many years. Our long-term sustainability depends on us operating responsibly and making a positive impact in the areas that are important to our company and our stakeholders.

We have a defined Environmental, Social and Governance (ESG) strategy — and we set measurable targets, many of which are tied to sustainable finance instruments, to hold us accountable and drive action. Here are some highlights of how we advanced these efforts last year..



Environmental-

Minimizing our impact on the planet

Reduced total scope 1 and 2 GHG emissions by **24%↓** (vs. 2019)

Reduced total scope 3 GHG emissions by **12%↓** (vs. 2020)

Increased total proportion of electricity purchased or generated from renewable sources to **41%↑**

Greenhouse gas (GHG) emissions reduction targets (scope 1, 2 and 3) validated by Science Based Targets initiative (SBTi)



Social-

Advancing health and equity



5 access to medicines programs launched as of 2022 (63% of 2025 target of 8 access programs)

30.4M doses of essential medicines (worth **\$11.5M**) donated to Ukrainian people, largest donation of any pharmaceutical company at the time



80%↓ reduction in total recordable incident rate, a measure of employee safety, over the last decade

82% employee satisfaction with Teva's inclusion and diversity practices

*Based on 2022 Teva Organizational Health Survey

21 new regulatory submissions in low- and middle-income countries (LMICs) (**28% of 2025 target**)



\$44B in savings from generic medicines across 21 countries



Governance-

Dedicating ourselves to quality, ethics and transparency

11.5% of procurement spend in the US allocated to small, diverse businesses



Approximately **100%** of active employees and **93.8%** of new employees trained on compliance policies



More than half of critical suppliers assessed on ESG performance (56% of 2025 target)